Overview

Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
To examine the safety and efficacy of long term administration of aripiprazole as an adjunctive therapy, co-administered with either a selective serotonin reuptake inhibitor (SSRI) or a selective-norepinephrine reuptake inhibitor (SNRI), in subjects with major depressive disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
Aripiprazole